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ALNC: Axillary and inguinal lymph node cell
Breg: Regulatory B
CS: Contact sensitivity
EAE: Experimental autoimmune encephalomyelitis
FACS: Fluorescence-activated cell sorting
i.p.: Intraperitoneal
i.v.: Intravenous
MLNC: Mesenteric lymph node cell
MPO: Myeloperoxidase
PP: Peyer patch
SFB: Segmented filamentous bacteria
SPLC: Splenocyte
TH: T helper lymphocyte
Treg: Regulatory T
TNP-Cl: Trinitrophenyl chloride
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122 STRZĘPA ET ALBackground: Medical advances in the field of infection therapy
have led to an increasing use of antibiotics, which, apart from
eliminating pathogens, also partially eliminate naturally
existing commensal bacteria. It has become increasingly clear
that less exposure to microbiota early in life may contribute to
the observed rise in ‘‘immune-mediated’’ diseases, including
autoimmunity and allergy.
Objective: We sought to test whether the change of gut
microbiota with the broad spectrum antibiotic enrofloxacin will
modulate contact sensitivity (CS) in mice.
Methods: Natural gut microbiota were modified by oral
treatment with enrofloxacin prior to sensitization with
trinitrophenyl chloride followed by CS testing. Finally, adoptive
cell transfers were performed to characterize the regulatory
cells that are induced by microbiota modification.
Results: Oral treatment with enrofloxacin suppresses CS and
production of anti–trinitrophenyl chloride IgG1 antibodies.
Adoptive transfer experiments show that antibiotic
administration favors induction of regulatory cells that suppress
CS. Flow cytometry and adoptive transfer of purified cells show
that antibiotic-induced suppression of CS is mediated by TCR
ab1CD41CD251FoxP31 Treg, CD191B2201CD51 IL-101, IL-
101 Tr1, and IL-101 TCR gd1 cells. Treatment with the
antibiotic induces dysbiosis characterized by increased
proportion of Clostridium coccoides (cluster XIVa), C coccoides–
Eubacterium rectale (cluster XIVab), Bacteroidetes, and
Bifidobacterium spp, but decreased segmented filamentous
bacteria. Transfer of antibiotic-modified gut microbiota inhibits
CS, but this response can be restored through oral transfer of
control gut bacteria to antibiotic-treated animals.
Conclusions: Oral treatment with a broad spectrum antibiotic
modifies gut microbiota composition and promotes anti-
inflammatory response, suggesting that manipulation of gut
microbiota can be a powerful tool to modulate the course of CS.
(J Allergy Clin Immunol 2017;140:121-33.)
Key words: Contact sensitivity, gut microbiota, immunoregulation,
dysbiosis, regulatory cells
Advances in medicine in the field of infection therapy over the
last several decades have led to a drastically increasing applica-
tion of antibiotics, which, apart from eliminating pathogens, also
partially eliminate naturally existing commensal bacteria. In
addition, unlabeled broad-spectrum antibiotics are often present
in the food supply, which also can change the composition of gut
microbiota. A study in a group of healthy human volunteers
showed that treatment with ciprofloxacin for 5 days decreases
diversity, richness, and evenness of fecal microbiota during
antibiotic treatment.1 Although the microbiota mostly returned
to pretreatment composition following ciprofloxacin treatment,
several bacterial taxa failed to recover, indicating that changes
to the microbiota can persist following a short course of oral an-
tibiotics.2 Similar to human studies, mouse models have revealed
that treatment with ampicillin, cefoperazone, vancomycin, or
clindamycin causes long-lasting changes in the gut microbiota
that persist after cessation of antibiotic treatment.3-5
It has become increasingly clear that less exposure to micro-
biota early in life may contribute to the observed rise in the
diseases characterized by immune dysregulation, including
allergy, autoimmunity, metabolic disorders, and even neoplastic
diseases.6 A number of studies have demonstrated the increasedrisk of developing asthma and food allergy in children who
have been exposed to antibiotics in the first year of life.7-9 Similar
findings are also observed in animal studies, such as in the non-
obese-diabetic mouse, which is known to be very sensitive to
the change of the environment, such that a cleaner environment
enhances the rate of onset and incidence of type 1 diabetes.10
This is also the case in animal models of allergic asthma.11,12
Studies carried out in recent years have confirmed a strong
connection between the natural gut microbiota and the immune
response. However, this interaction may differ in various experi-
mental models. In an animal model of multiple sclerosis, for
instance, a strong inhibition of inflammation has been observed
in mice treated orally with an antibiotic.13 Similar observations
have been reported in an animal model of human rheumatoid
arthritis.14
Atopic dermatitis (AD) is a prominent clinical example of an
immune-mediated disease that is affected by environmental
factors. AD has become a considerable clinical problem, having
nearly tripled in prevalence over the last 30 years in developed
countries. The disease afflicts 15% to 30% of children and about
2% to 10% of adults.15 Yet another form of skin disease with an
underlying immune-mediated hypersensitivity reaction is contact
sensitivity (CS) to haptens. Allergic contact dermatitis, as
opposed to AD, is a typical CS response in humans and has
become a significant cause of morbidity. Indeed, contact derma-
titis linked to exposure to chemical substances in the workplace
constitutes about 30% of all occupational diseases and represents
a severe social and economic problem.16
The hygiene hypothesis has been advanced as an explanation
for the dramatic rise in the prevalence of allergic diseases in
industrialized societies. Supporters of this hypothesis note that
decreasing microbial exposure of many types, including bacteria,
parasites, and viruses, has been associated with the rise in
incidence of allergic diseases and autoimmune disorders.17
Increasing evidence suggests that gut microbes, which represent
an enormous source of interaction between microbes and immu-
nity, play a very important role in various health problems.6 How-
ever, it is not clear what effects are exerted by natural gut
microbiota on the course of CS responses. Given the common
use of antibiotics in industrialized societies, in the setting of
ever-increasing exposure to potential CS-generating haptens in
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tant to study the effect of the gutmicrobiota on the CS response. In
the current article, therefore, we test our hypothesis that change of
gut microbiota with a broad spectrum antibiotic will modulate CS
response in mice.METHODS
Mice
C57BL/6 mice, at 6 weeks old, were taken from the breeding unit of the
Department of Medical Biology, Jagiellonian University, College of Medi-
cine. Micewere kept under pathogen-free conditions in individual cages using
Aero-Mouse IVC Green Line system (Tecniplast SpA, Buguggiate, Italy). All
experiments were conducted in compliance with the guidelines of the First
Local Ethics Committee of the Jagiellonian University Medical College.Reagents
Trinitrophenyl chloride (TNP-Cl) (Chemica Alta, Edmonton, Alberta,
Canada); Evans blue, formamide, hexadecyltrimethylammonium bromide,
lysozyme, magnesium chloride, JumpStart Taq ReadyMix for quantitative
PCR, o-dianisidine dihydrochloride, sodium dodecyl sulfate, Tris-EDTA, and
hydrogen peroxide were obtained from Sigma (St Louis, Mo). Silica beads
were from BioSpec Products (Bartlesville, Okla); proteinase K was from
Roche Diagnostics (Mannheim, Germany). Baytril (enrofloxacin) was pur-
chased from Bayer Animal Healthcare GmbH (Leverkusen, Germany).Sensitization and elicitation of CS in vivo
Contact sensitivity to TNP-Cl was induced as described previously.18
Vascular permeability, myeloperoxidase (MPO) assay, and concentration of
IFN-g was measured as previously described.18Treatment with enrofloxacin
Mice received drinking water containing the broad spectrum antibiotic
enrofloxacin (0.27 mg/mL) or water alone for 2 weeks prior to sensitization
with TNP-Cl. In some experiments, mice received enrofloxacin intraperito-
neally ([i.p.]; 5 mg/kg) or PBS for 2 weeks prior to further tests.Evaluation of gut flora depletion
Serial dilutions of colon contents from enrofloxacin-treated or untreated
mice were cultured on general agar plates (blood agar, Bioshop Inc,
Burlington, Ontario, Canada) at 378C for 48 hours or 72 hours in aerobic
and anaerobic conditions, respectively. Total bacteria per gram of sample was
calculated using colony forming unit.
Adoptive cell transfer of CS and cell mixing assay to
evaluate suppression (transfer out protocol). Donors of
CS-immune effector cells were contact sensitized with 5% TNP-Cl. Axillary
and inguinal lymph nodes (ALNs)were harvested fromTNP-Cl-immunemice
on day14, and 73 107 immune cells were incubated for 30minutes at 378C in
RPMI 1640 medium alone, washed, and then injected i.v. into normal synge-
neic recipients (positive transfer). For the cell mixing assay, 73 107 of the CS-
effector immune cells from TNP-Cl contact sensitized donors were incubated
for 30 minutes at 378C with 5 3 107 ALNCs or splenocytes (SPLCs), or
1 3 107 Peyer patch (PP) cells or mesenteric lymph node cells (MLNCs),
frommice treated orally with enrofloxacin for 2 weeks prior to TNP-Cl immu-
nization. After incubation, the cell mixture was transferred i.v. into naive re-
cipients. Mice were challenged with the hapten within 30 minutes after cell
transfer and tested for CS 24 hours later.
Transfer of regulatory cells prior to CS induction or
elicitation to confirm active tolerance (transfer in pro-
tocol). To confirm data found in the ‘‘transfer out’’ cell mixing assay,
53 107 ALNCs or SPLCs, or 13 107 PP cells or MLNCs, isolated from do-
nors orally treatedwith enrofloxacin for 2 weeks prior to TNP-Cl sensitization,were transferred i.v. into syngeneic recipients 2 hours prior to CS induction, or
1 day prior to CS elicitation (day13).Mice then underwent allergen challenge
on the ears and were tested for CS. In some experiments, cell populations pu-
rified by magnetic cell sorting were transferred as indicated to characterize
their regulatory activity.Extraction of bacterial DNA from the gut content
Gut content was collected by lavage with sterile PBS and centrifuged. The
pellet was resuspended in sterile PBS and mixed vigorously. After centrifu-
gation, the supernatant without the solid fraction was collected and
centrifuged. The pellet was resuspended in 300 mL of Tris-EDTA. Samples
were frozen and thawed several times followed by chemical disruption with
lysozyme and SDS, followed by protein removal using silica beads. DNA
extraction with phenol-chloroform-isoamyl alcohol (25:24:1) solution was
performed as described elsewhere.PCR conditions
To evaluate dysbiosis after oral antibiotic administration, RT-PCR was
performed with 10.5 ng of DNA using CFX96 Touch (Bio-Rad Laboratories,
Inc, Hercules, Calif). Detection of selected gut bacteria species and group was
based on amplification of conserved 16S ribosomal DNA fragments. The
primer sequences are summarized in Table E1 found in this article’s Online
Repository at www.jacionline.org. PCR conditions were as described previ-
ously.19,20 The 16S ribosomal DNA detected by universal primers and probes,
detecting all bacteria, was used as the reference gene.21 The expression level
was determined by the values received from mixed DNA samples extracted
from control mice and presented as DDct.22 Values for all bacteria were sub-
tracted from values obtained for selected bacteria.23Transfer of gut microbiota
Cohousing was performed by housing mice given oral enrofloxacin with
untreated animals for 2 weeks prior to TNP-Cl sensitization and CS test. The
experiment of ‘‘adoptivemicrobiota transfer’’ (fecalmicrobiota transplantation)
was performed by oral gavagewith the fecal material from the donors that were
or were not treated per os with enrofloxacin. Twenty-four hours after stopping
enrofloxacin, the lumen contents of the large intestinewere harvested in 4mLof
sterile PBS, mixed vigorously, and centrifuged. The fecal supernatant (300mL)
was orally inoculated twice a week for 2 weeks24 prior to CS induction.Statistics
Data in graphs are shown as mean6 SE. Student t test or ANOVA followed
by Tukeymultiple comparison test was used. Statistical significancewas set at
P < .05.
Description of all of the materials and methods used in this study can be
found in the Methods section in this article’s Online Repository at www.
jacionline.org.RESULTS
Oral application of broad spectrum antibiotic
enrofloxacin alleviates CS in mice
To determine the influence of gut microbiota on CS, mice were
treated orally or i.p. with the broad spectrum antibiotic enroflox-
acin prior to TNP-Cl sensitization. Oral treatment with enroflox-
acin reduced CS, as measured by ear swelling, in actively
immunized mice (Fig 1 A, Group D vs B), whereas i.p. injection
of enrofloxacin does not affect ear swelling (Group F vs B). Both
oral or i.p. enrofloxacin treatment did not affect the body weight
of mice, regardless of TNP-Cl immunized, when compared with
animals not treated with enrofloxacin (Fig 1,B, Groups C and E vs
A and Groups D and F vs B). Oral antibiotic application
FIG 1. Oral application of broad spectrum antibiotic alleviates CS in mice. Mice received plain water
(Groups A and B) or water containing enrofloxacin (0.27 mg/mL) (Groups C and D), or they were i.p. injected
with enrofloxacin (5 mg/kg) (Groups E and F) for 2 weeks prior to TNP-Cl or sham immunization and test. A,
Ear swelling. B, Body weight. C and D, Aerobic and anaerobic bacteria in content of large intestine. E, Adop-
tive transfer of CS. F, Production of TNP-specific IgG1 and IgG2a. Results shown as mean 6 SE. n 5 8 to 16
(A), n 5 5 to 6 (B-D), n 5 14 (E), and n 5 5 to 7 (F). *P < .05, **P < .01, and ***P < .001.
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anaerobic (Fig 1, D) bacteria in colon contents (Groups C and
D vs A and B). Intraperitoneal injection of antibiotic did not affect
bacterial counts of aerobes (Fig 1, C) and anaerobes (Fig 1, D,
Groups E and F vs A and B). A decrease of CS in actively immu-
nized mice due to antibiotic treatment was confirmed by adoptive
lymphocyte transfer experiments. Transfer of axillary and
inguinal lymph node cells (ALNCs) and SPLCs isolated from
TNP-Cl sensitized donors that were orally treated with enroflox-
acin to naive mice significantly reduced CS when compared with
positive control (ALNC and SPLC from hapten-sensitized mice
not treated with antibiotic) (Fig 1, E, Group C vs B). Additionally,
oral treatment with antibiotic prior to CS induction and elicitation
increased production of TNP-specific IgG1 antibodies but
reduced synthesis of anti-TNP IgG2a antibodies (Fig 1, F, Group
C vs B). The ear swelling data were confirmed in further experi-
ments showing that oral treatment with enrofloxacin prior to TNP-
Cl sensitization results in decreased vascular permeability
(Fig 2,A) and lower ear weight (Fig 2,B). Additionally, oral appli-
cation of enrofloxacin before induction of CS resulted in reduced
MPO activity, as well as decreased IFN-g concentration in ear ex-
tracts (Fig 2, C and D).
Oral treatment with antibiotic induces cells that
inhibit CS in vivo. To test whether decreased CS responsesafter antibiotic treatment can be transferred into naive recipients,
we performed adoptive transfer (‘‘transfer out’’) experiments, in
which naive recipient mice were given TNP-Cl immune cells
(7 3 107 cells) that were preincubated with ALNCs or SPLCs
(53 107), or MLNCs (13 107 cells), or PP-derived lymphocytes
(1 3 107 cells) isolated from syngeneic animals that were orally
treated with antibiotic and sensitized with TNP-Cl (Fig 3, A,
Groups C-F). The recipient mice were tested for CS immune
response after cell transfer. Mice in the positive control group
received immune cells only (Group B). ALNCs, SPLCs, MLNCs,
and PP cells from donors treated with antibiotic prior to TNP-Cl
immunization inhibit the effector function of TNP-Cl-sensitized
CS-effector cells (Fig 3, A, Groups C-F vs B). Additionally, em-
ploying a ‘‘transfer in’’ protocol, we showed that injection of
ALNCs, SPLCs, MLNCs, or PP cells isolated from donors treated
with antibiotic and sensitized with TNP-Cl into actively sensi-
tized recipients 1 day before allergen challenge to the ear
(day 13) suppressed CS response (Fig 3, B, Groups C-F vs B).
Our results suggest that cells from antibiotic-treated mice prior
to TNP-Cl sensitization suppress the effector phase of the CS
response. To determine whether the antibiotic-induced cells
also play a role during the CS induction phase, ALNCs, SPLCs,
MLNCs, and PP cells isolated from mice receiving antibiotic
prior to TNP-Cl sensitization were transferred into syngeneic
FIG 2. Oral treatment with antibiotic prior to CS induction inhibits inflammatory response in the ears. A,
Vascular permeability. B, Ear weight. C, MPO activity in ear extracts. D, IFN-g concentration in ear extracts.
Results shown as means 6 SEs. n 5 10 to 14 (A, B, and D), n 5 12 (C). *P < .05 and ***P < .001. U, Unit.
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FIG 3. Oral treatment with antibiotic induces cells that suppress CS in vivo. Transfer of ALNCs or SPLCs or
MLNCs or PP cells from donors treated orally with enrofloxacin and then sensitized. A, ‘‘Transfer out.’’ B,
‘‘Transfer in’’ prior to allergen challenge. C, ‘‘Transfer in’’ prior to immunization. Results shown as
means 6 SEs. n 5 10 to 14 (A and B), n 5 8 to 12 (C). *P < .05 and ***P < .001.
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transferred cells interfere with the induction phase of the CS
response (Fig 3, C, Groups C-F vs B).
Oral antibiotic treatment prior to TNP-Cl sensitiza-
tion induces distinct populations of regulatory cells. As
shown above, pretreatment with antibiotic prior to hapten sensiti-
zation results in the induction of regulatory cells in ALN, SPL,
MLN, and PP. To determine which type of the regulatory cells is
involved in the suppression of CS in our model, we phenotyped
ALN, SPL, MLN, and PP cells by flow cytometry after staining
with different fluorochrome-conjugated antibodies. Gating strategy
is provided in Fig E1 in this article’s Online Repository at www.
jacionline.org. We found that the percentage of both TCR
ab1CD41CD251FoxP31 regulatory T (Treg) and CD191B2201
CD51IL-101 regulatory B (Breg) cells in PP were increased in
mice orally treated with antibiotic followed by TNP-Cl sensitiza-
tion when compared with hapten-sensitized mice that had notbeen treated with antibiotic (Fig 4, A, Group D vs B). Moreover,
we observed nonsignificant increase of TCR ab1CD41CD251
FoxP31 Treg cells in PP in mice treated with antibiotic without
hapten sensitization, compared with the antibiotic-untreated mice
(Fig 4, A, Group C vs A). Fluorescence-activated cell sorting
(FACS) analysis of MLN showed that antibiotic treatment and
hapten sensitization increased the frequency of both TCR
ab1CD41CD251FoxP31 Treg and TCR ab1CD41IL-101 Tr1
cells when compared with antibiotic-untreated, hapten-sensitized
mice (Fig 4, B, Group D vs B). Interestingly, we also found an
increased frequency of TCR gd1 IL-101 lymphocytes in ALN
and SPL of antibiotic-treated, hapten-sensitized mice compared
with the animals with hapten sensitization in the absence of anti-
biotic treatment (Fig 4, C and D, Group D vs B).
Adoptive transfer of purified regulatory cell popula-
tions inhibits CS in vivo. To test the suppressive function of
the regulatory cells induced by antibiotic treatment, we purified
FIG 4. Oral treatment with antibiotic prior to TNP-Cl sensitization induces various populations of regulatory
cells. Water (Groups A and B) or water with enrofloxacin (Groups C and D) receiving mice were (Groups B
and D) or were not (Groups A and C) sensitized with TNP-Cl prior to FACS analysis of lymphoid organs. A,
Percentage of TCR ab1CD41CD251FoxP31 Treg and CD191B2201CD51IL-101 Breg cells in PP. B, Percentage
of TCR ab1CD41CD251FoxP31 Treg and TCR ab1CD41IL-101 Tr1 cells in MLN. C, Percentage of TCR gd1IL-
101 lymphocytes in ALN. D, Percentage of TCR gd1IL-101 lymphocytes in SPL. Results shown as
means 6 SEs. n 5 4 to 5. *P < .05 and **P < .01.
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and hapten-sensitized donors and then transferred CD41CD251
(3.9 3 105), CD191 (3.3 3 105), or whole PP cells (1 3 107)
into naivemice prior to TNP-Cl immunization. Each of these pop-
ulations suppressed CS, although the suppression by
CD41CD251 cells was greater (Fig 5, A, Groups D and E vs
B). Our results suggest that Treg and Breg cells may be involved
in the observed immunoregulation. We also tested the regulatory
cells from MLN using the same approach. Total MLNCs
(1 3 107) and purified CD41CD251 cells (6 3 105) from
MLNs of antibiotic-treated and hapten-sensitized mice equally
inhibited CS reactions in the recipients (Fig 5, B, Group D vs
B). Finally, we tested the immune regulatory function of the
TCR gd cells that were observed to be increased after antibiotic
treatment. We found that transfer of 5 3 107 unpurified ALNs
or SPLCs of antibiotic-treated and hapten-sensitized donors
downregulated CS response in the recipient mice (Fig 5, C and
D, Group C vs B). Similar to the unpurified ALNs and SPLCs, pu-
rified TCR gd from ALNs (1.5 3 106) or SPLCs (1 3 106) of
antibiotic-treated and hapten-sensitized donors downregulated
CS response in the recipient mice (Fig 5,C andD, Group D vs B).
Treatment with antibiotic shifts the bacterial popu-
lation toward an anti-inflammatory profile. Oral anti-
biotic treatment significantly reduced both aerobic and
anaerobic bacteria number in the gut. Recent studies indicate
that some gut bacteria can promote anti-inflammatory re-
sponses, whereas others can induce inflammatory reactions.25To test whether the observed downregulated CS response in
antibiotic-treated mice is the result of dysbiosis, we evaluated
the composition of some common gut microbiota using
RT-PCR. We found that some species of gut bacteria changed
significantly between treated and untreated mice, whereas other
bacterial species remained unaffected (Fig 6). Among the tested
species, the relative abundance of Enterococcus spp and Lacto-
bacillus were similar between untreated and antibiotic-treated
mice (Fig 6, A, Group B vs A), whereas antibiotic treatment
significantly increased the relative abundance of Clostridium
coccoides (cluster XIVa) and C coccoides–Eubacterium rectale
(cluster XIVab) compared with untreated mice (Fig 6, B, Group
B vs A). Antibiotic treatment also increased the relative abun-
dance of Bacteroidetes and Bifidobacterium spp compared
with untreated mice (Fig 6, C, Group B vs A). In contrast, anti-
biotic treatment significantly decreased the relative abundance
of segmented filamentous bacteria (SFB) compared with the
control mice (Fig 6, D, Group B vs A).
Direct transfer of gut flora modulates CS response
in vivo. To determine the direct role of gut microbiota in
downregulation of CS response associated to antibiotic treatment,
we took 2 approaches to foster microbiota exchange between
mice. First we performed a cohousing experiment by keeping
mice that were previously antibiotic-treated or untreated for
2 weeks in the same housing, followed by sensitization with TNP-
Cl and testing for CS immune response. We found that naive mice
cohoused with antibiotic-treated animals show decreased CS
FIG 5. Transfer of purified regulatory cells prior to TNP-Cl immunization inhibits CS in vivo. Whole immune
cells from PP, MLN, ALN, or SPL or adequate magnetic cell sorting-purified cells from each organ were
transferred to naive recipients prior to hapten immunization and CS test. A, Transfer of purified CD41
CD251 or CD191 cells from PP. B, Transfer of purified CD41 CD251 cells from MLN. C, Transfer of purified
TCR gd from ALN. D, Transfer of purified TCR gd from SPL. Results shown as means 6 SEs. n 5 8. *P < .05,
**P < .01, and ***P < .001.
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FIG 6. Treatment with antibiotic shifts the bacteria profile toward anti-inflammatory flora in mice treated
with water containing enrofloxacin. Relative abundance of bacterial-conservative 16S rDNA fragments in
gut: A, Lactobacillus and Enterococcus spp; B, C coccoides (cluster XIVa) and C coccoides–E rectale (cluster
XIVab); C, Bacteroidetes and Bifidobacterium spp; D, SFB. Results shown as means 6 SEs. n 5 11. *P < .05
and **P < .01.
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pression of CS response in this group was similar to the suppres-
sion seen in the antibiotic-treated mice with or without cohousing
(Fig 7,A, Group E vs C, D, and F). Next, we transferred gutmicro-
biota from the mice with or without antibiotic treatment directly
to naive mice through oral gavage, followed by induction of the
CS response. The mice that received gut bacteria from
antibiotic-treated donors showed decreased CS after TNP-Cl
sensitization (Fig 7,B, Group C vs B), whereas therewas no effect
on CS response when the naive recipients were given gut mi-
crobes from non-antibiotic-treated donors (Fig 7, B, Group D vs
B). Furthermore, the suppressed CS response seen in antibiotic-
treated mice was reversed by oral transfer of gut microbes from
non-antibiotic-treated mice (Fig 7, C, Group E vs C and D),
whereas gavage of naive mice with gut flora from non-
antibiotic-treated control animals did not affect CS (Fig 7, C,
Group F vs B).DISCUSSION
There is mounting evidence that the homeostasis of the gut
microbiome is important for the balance and regulation of the
immune system in both animals and humans. Recent studies haveshown that microbiota play a crucial role in fostering the
development of numerous T-cell subsets including TH17 and
Treg lymphocytes.26 Germ-free mice have imbalanced TH1/
TH17 responses that are beneficial in some autoimmune disorders,
including experimental autoimmune encephalomyelitis (EAE)
and collagen-induced arthritis,27,28 but that appear to be
detrimental for others, such as type 1 diabetes. The involvement
of microbiota in the development of autoimmunity and other
immune-mediated diseases has also been revealed by observing
the effect of removing some gut bacteria with antibiotics.13,14 It
has been shown that adult mice treated with broad spectrum anti-
biotics develop ameliorated forms of animal models of TH17-
mediated psoriasis29 and TH1-mediated EAE
13 but show no ef-
fects in TH2-mediated allergic responses.
30 On the other hand,
broad spectrum antibiotics administrated early in life increase
susceptibility to TH17-mediated psoriasis
29 and to TH2-mediated
AD.30 Increasing evidence suggests that imbalance in homeosta-
sis of gut bacterial species is associated with atopic disor-
ders.12,31,32 Metagenome sequence analyses of the gut
microbiome from patients with AD showed that enrichment of
a subspecies of the major species of gut bacteria Faecalibacte-
rium prausnitzii is strongly associated with AD.33 It has been re-
vealed that operational taxonomic units belonging toF prausnitzii
FIG 7. Transfer of gut flora modulates CS response in vivo. A, Cohousing experiment. B, Transfer of gut
flora from enrofloxacin-treated donor mice. C, Transfer of gut flora from naive mice. Results shown as
means 6 SEs. n 5 10 to 12 (A), n 5 10 to 14 (B), n 5 8 (C). *P < .05, **P < .01, and ***P < .001. FMT, Fecal
microbiota transplantation.
J ALLERGY CLIN IMMUNOL
JULY 2017
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biota. Song et al33 postulate that interactions between dysbiosis in
F prausnitzii and dysregulation of gut epithelial inflammation
might underlie the chronic progression of AD.
The influence of microbiota on CS response is not well
explored. A few studies suggest that the proliferation of Bifido-
bacterium pseudolongum in the intestinal tract could be partially
responsible for the reduction of 2,4-dinitro-1-fluorobenzene–
induced CD8 Tc1-mediated CS response in mice,34,35 and oral
administration of the probiotic Lactobacillus casei alleviates
CD8 Tc1-mediated CS to 2,4-dinitro-1-fluorobenzene.36
Currently there are no studies, however, investigating the role
of microbiota in CD41 TH1-mediated CS responses. The novel
findings of our study are, first, that the same antibiotic, enroflox-
acin, administrated via different routes leads to different effectson CS in vivo. Second, we show that oral administration of enro-
floxacin disturbs the natural composition of gut microbiota and
induces different regulatory immune cells that suppress CS in-
flammatory response. Third, we show that the suppression of
CS inflammatory response can be transferred to a new host by
each population of regulatory cells. Fourth, we show that co-
housing the mice with altered gut microbiota or fecal matter
transfer can confer the protection to the new hosts. Finally, we
show that the anti-inflammatory effect mediated by altered gut
microbiota can be reversed by introducing normal gut micro-
biota. It is interesting that systemic administration of the same
antibiotic, through i.p. injection, did not affect CS response
in vivo, suggesting the importance of antibiotic activity within
the intestinal lumen. Our study provides strong evidence that
gut microbiota play an important role in skin allergic
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sponses after treatment with enrofloxacin prior to TNP-Cl sensi-
tization in mice with highly divergent MHC haplotypes, namely
non-obese-diabetic and BALB/c mice, suggesting that the
observed phenomenon does not depend on theMHC background
(data not shown).
The treatment with the antibiotic either orally or i.p. did not
affect animal body weight, suggesting that the observed modula-
tion of the CS response is not a result of side effects related to anti-
biotic treatment. The culture of gut content showed that oral but
not i.p. administration of the antibiotic significantly reduced the
number of both aerobic and anaerobic gut bacteria. Our findings
are in line with recent data showing that reduction of gut
commensal bacteria after oral, but not i.p., treatment with anti-
biotic impairs the development of EAE.13 Analyzing the compo-
sition of gut microbiota, we find an increase of Bifidobacterium
spp, in agreement with the study by other investigators showing
that consumption of prebiotic fructo-oligosaccharide, which is
associated with proliferation of B pseudolongum in the intestinal
tract of mice, reduces CS.37
The CS seen after transfer of ALNC and SPLC from
antibiotic-treated and TNP-Cl-sensitized mice is weaker
compared with CS after transfer of ALNC and SPLC isolated
from non-antibiotic-treated, TNP-Cl-sensitized mice. Howev-
er, this experiment did not answer the question of whether
antibiotic treatment prior to hapten sensitization affects the
induction of CS-effector cells themselves or is involved in the
induction of regulatory cells. To answer this question, 2
approaches have been taken in our study. Using a ‘‘transfer
out’’ protocol, we show that cotransfer of CS-effector cells
with immune cells (ALNC or SPLC or MLNC or PP cells)
isolated from antibiotic-treated donors results in decreased CS
response when compared with the control mice that received
CS-effector cells alone. This strongly suggests that immune
cells from antibiotic-treated mice contain regulatory cells. Our
results further demonstrate that the regulatory cells can act
at both the induction and the effector phases of the CS
response. Phenotyping the immune cells revealed an increased
percentage of TCR ab1CD41CD251FoxP31 Treg cells in
both MLN and PP of antibiotic-treated mice compared with
nontreated mice. This is also in line with a study by Ochoa-
Reparaz et al13 that shows an increase of Foxp31 Treg cells
in MLN and cervical LN of antibiotic-treated mice. In addition
to Foxp31 Treg cells, we observe an increase of TCR
ab1CD41IL-101 lymphocytes in MLN of antibiotic-treated
mice compared with nontreated mice. Our results suggest
that alteration of gut microbiota can induce both TCR
ab1CD41CD251FoxP31 Treg cells in MLN and IL-101 Tr1
cells.38 Interestingly, phenotypic analysis in our study also re-
veals an increase of Breg cells that are CD191B2201CD51IL-
101 in PP of antibiotic-treated mice. A study in an EAE model
system has shown that antibiotic-treated mice have an
increased percentage of CD191B2201, IL-10-producing,
CD51 Breg cells in peripheral lymph organs.39 It has been re-
ported that CD191 B cells also can negatively regulate CS re-
sponses.40 Our results further indicate that IL-10-producing
TCR gd1 cells are among the immune regulatory cells from
antibiotic-treated mice. Our findings add another population
of microbiota-associated regulatory cells that has not beenappreciated to date. We have reported previously the involve-
ment of TCR gd cells in negative regulation of CS response.41
Our current study indicates that oral administration of anti-
biotic prior to hapten sensitization induces 4 different subsets
of regulatory cells. In this study, we show the ability of these 4
populations to suppress the CS response in vivo by transferring
each purified cell subset individually. These experiments prove
that each cell population indeed has the ability to suppress the
CS response in vivo after adoptive transfer. Our study also pro-
vides evidence that alteration of gut microbiota due to the oral
administration of antibiotics may affect the development of
regulatory cells.
It is known that antibiotic treatment decreases not only the
number of bacteria but also the diversity of the microbiota.
This effect can last from days to weeks after the cessation of
antibiotic administration, and it is possible that some bacterial
species could be depleted from the community permanently.42
Moreover, antibiotics can affect the immune system, favorably
or harmfully, through the change of bacterial composition.
Recent studies have shown that Bacteroides fragilis increases
the suppressive activity of Treg cells, whereas certain Clos-
tridium strains increase the frequency of IL-10-producing
Tregs.43,44 Other studies reported that gavage of commensal
bacteria of the Lactobacillus or Bifidobacterium genera can
induce Treg cells.45,46 However, the studies of SFB in mice
have demonstrated that SFB is closely associated with the in-
duction of TH17 lymphocytes.
47 In this study, we demonstrate
that oral treatment with the antibiotic increases the relative
abundance of C coccoides (cluster XIVa), C coccoides–E rec-
tale (cluster XIVab), Bacteroidetes, and Bifidobacterium spp,
all of which have been shown to promote anti-inflammatory re-
sponses.25 In contrast, oral antibiotic treatment decreases the
relative abundance of SFB, which are known to promote IL-
17-mediated inflammatory response.47 Our results suggest
that antibiotic-induced dysbiosis of gut microbiota favors an
anti-inflammatory status and ameliorates contact sensitivity
of skin inflammatory response. This is further confirmed by
cohousing naive mice with antibiotic-treated mice and by gut
microbiota transfer from antibiotic-treated mice to naive
mice, both of which suppress CS responses in naive mice.
More importantly, we show that the CS response can be
restored through oral transfer of control gut bacteria to
antibiotic-treated animals, suggesting that changes in the gut
flora can revert to a natural homeostatic state through oral
transfer. It is noteworthy that the route of antibiotic administra-
tion is essential for our findings presented in this study, as sys-
temic antibiotic administration via the i.p. route had little
effect on the immune regulation of CS.
In summary, our work shows that oral treatment with the broad
spectrum antibiotic enrofloxacin modifies gut microbiota compo-
sition to promote an anti-inflammatory response as seen in
reduced CS responses. The observed changes in microbiota
promote the induction of different populations of regulatory cells
that inhibit CS in vivo. The suppression of the CS response
induced by antibiotic effects on the microbiota is reversible, as
gavage of antibiotic-treated mice with control gut flora restores
CS reactions. Thus, targeted manipulation of gut microbiota,
leading to increased level of anti-inflammatory bacteria could
be a therapeutic strategy to ameliorate allergic contact dermatitis.
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Key messages
d Oral treatment with broad spectrum antibiotic enrofloxa-
cin leads to gut dysbiosis associated with increased levels
of anti-inflammatory bacteria.
d An alteration in gut microbiota profile favors induction of
a variety of regulatory cells that inhibit CS in mice.
d Transfer of antibiotic-modified gut microbiota inhibits
CS, indicating that targeted modulation of gut microbiota
could have therapeutic potential.
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METHODS
Sensitization and elicitation of CS in vivo
Mice were sensitized by topical application of 0.15 mL of 5% TNP-Cl in
acetone-ethanol mixture (1:3) to the shaved abdomen and chest. Control
mice were shaved and painted with the acetone-ethanol mixture alone as a
sham sensitization. Four days later, animals were challenged on both sides
of the ears with 10 mL of 0.4% TNP-Cl in olive oil–acetone mixture (1:1).
Resulting ear thickness was measured prior to testing with a micrometer
(Mitutoyo, Tokyo, Japan) by an observer unaware of the experimental
groups and then again at 24 hours after allergen challenge. Negative control
consisted of littermate sham-sensitized animals that were similarly chal-
lenged. The ear swelling was expressed in mm 6 SE.E1 Ear swelling was
further confirmed by the measurements of ear weight, vascular permeability,
MPO activity, and IFN-g concentration in ear extracts. Additionally, concen-
trations of anti-TNP IgG1 and IgG2a were measured in mouse sera by
ELISA. The immunomodulatory influence of microbiota on the severity
of CS was evaluated by detection of gut bacteria composition using PCR.
The primers sequences used to detect selected gut bacteria species are pro-
vided in Table E1.
Vascular permeability test
To assess very early changes in vascular permeability, TNP-Cl immu-
nized or naive mice were challenged with 10 mL of 0.4% TNP-Cl and
injected with 1% Evans blue dye (83 mg/g body weight) 23 hours later. One
hour after Evans blue injection, mice were anesthetized and sacrificed. Ears
were removed, and a 6-mm diameter punch from each ear was made with
biopsy punch (cat# BP60; Fray Products Corp, Buffalo, NY). Ear punches
were transferred to tubes containing 1 mL of formamide. After 18 hours’
incubation at 378C, the samples were centrifuged and the optical density of
Evans blue in the supernatant was read at 565 nm against a blank containing
formamide.E1
MPO assay
Neutrophil infiltration to the inflamed ears was indirectly quantitated using
a MPO assay, as described previously.E1 Ears were removed 24 hours post
allergen challenge, and a 6-mm diameter punch from each ear was made. Bi-
opsies were collected from the distal site of CS responses and were homoge-
nized in 0.5% hexadecyltrimethylammonium bromide pH 5 6.0 (50 mg of
tissue/mL). The homogenates were freeze-thawed 3 times, centrifuged at
40,000g. Then 0.1-mL aliquots were mixed with 2.9 mL of phosphate buffer
(pH 5 6.0) containing 0.167 mg/mL o-dianisidine dihydrochloride and
5 3 1024% H2O2 and incubated at 258C for 20 minutes. The absorbance
was measured at 460 nm in 96-well flat bottom plates. MPO activity was ex-
pressed in units per protein concentration (U/mg of protein).
In vitro measurement of IFN-g in CS ear extracts
To determine local production of IFN-g in elicited TNP-Cl CS, mice
were immunized with 5% TNP-Cl or sham-sensitized and allergen
challenged with 10 mL of 0.4% TNP-Cl 4 days later. Ears were removed
24 hours post allergen challenge, and a 6-mm diameter punch from each ear
was made. Biopsies were collected from the distal site of CS ear responses.
The biopsies were frozen rapidly in liquid N2 and were subsequently thawed
and extracted in 300 mL of cold PBS containing a mixture of proteinase in-
hibitors on ice with a tissue microhomogenizer.E1 Concentration of IFN-g
was measured by ELISA with the use of BD OptEIA Set (BD Biosciences,
San Diego, Calif).
FACS analysis
ALNs, SPLs, MLNs, and PPs were isolated and single-cell suspensions
prepared and stained prior to analysis. Cell subpopulations were analyzed
using fluorochrome-conjugated mAbs. For the analysis of T-cell subpopula-
tions, CD4-PerCP-Cy5.5 and TCR b-APC-Cy7 (BioLegend, San Diego,
Calif), CD25-APC, and TCR gd-PE (BD Biosciences, San Jose, Calif) and
CD4-FITC (Life Technologies Corporation, Carlsbad, Calif) were used. For
B-cell identification, B220-PE-Cy7 and CD19-PerCP-Cy5.5 (eBioscience
Inc, San Diego, Calif) and CD5-FITC (BD Biosciences) were used.
Treg cells were determined by staining with anti-FoxP3-PE mAb (BD
Biosciences) using the mouse Treg staining kit (eBioscience) according to
manufacturers’ instructions. To detect intracellular IL-10, intracellular cyto-
kines staining was performed. Single-cell suspension from lymphoid tissues
were cultured for 4 hours with phorol 12-myristate 13-acetate, ionomycin
(Sigma Chemical Co, St. Louis, Mo), and Golgi Plug (eBioscience), followed
by surface-markers staining of TandB cells. Afterwashing, the cells were fixed
and permeabilized followed by staining with IL-10-PE-Cy7 or IL-10-PE. The
cells were analyzed with a FACS Canto II (Becton Dickinson, Franklin Lakes,
NJ) and data were analyzed using FACSDiva software (Becton Dickinson).
Gating strategies are provided in Fig E1.
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FIG E1. Representative flow cytometry gating strategies for: A, TCR ab1CD41CD251FoxP31 Treg; B, IL-101
TCR gd1 cells; C, CD191B2201CD51IL-101 Breg; D, TCR ab1CD41IL-101 Tr1. FSC-A, Foward scatter; SSC-A,
side scatter; TcRgd, TCR gd.
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TABLE E1. The primers sequences used to detect selected gut bacteria species
Primers
C coccoides–E rectale subgroup (cluster XIVab) F: 59-AAATGACGGTACCTGACTAA-39
R: 59-CTTTGAGTTTCATTCTTGCGAA-39
C coccoides (cluster XIVa) F: 59-AAATGACGGTACCTGACTAA-39
R: 59-CTTTGAGTTTCATTCTTGCGAA-39













F, Forward primer; FAM, 6-carboxyfluorescein; R, reverse primer; TAMRA, tetramethylrhodamine.
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